Mitchell Von Itzstein

Mitchell Von Itzstein, M.D., is an Assistant Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, specializing in Hematology and Oncology. He focuses on lung cancer treatment, immunotherapy, targeted therapies, and clinical trials, with over 40 peer-reviewed publications. His research interests include biomarker development, AI applications in medicine, and improving patient outcomes through novel therapies.

Education:

• Bachelor’s in Pharmaceutical Science (Griffith University)
• Master’s in Pharmacy (Griffith University)
• M.D. (Griffith University, with University Medal for Academic Excellence)
• Internal Medicine Residency (UT Southwestern)
• Medical Oncology Fellowship (UT Southwestern)

Research Interests: Lung cancer therapies, immune-checkpoint inhibitors, AI-driven clinical decision-making, and biomarker discovery. His work bridges translational research and clinical practice, emphasizing patient safety and equity in oncology care.

Publications: Over 40 articles, including studies on immune-related adverse events, antibody profiles in cancer patients, and racial disparities in immune parameters. Recent work explores combination therapies for KRAS-mutant lung cancer and AI chatbots for toxicity management.

Awards: University Medal for Academic Excellence (Griffith University).

Grants & Clinical Trials: Principal investigator on multiple clinical trials, including trials evaluating selinexor in lung cancer and biomarker studies using BCR sequencing.

Labs/Teams: Member of the Division of Hematology and Oncology at UT Southwestern, collaborating on translational oncology and precision medicine initiatives.